Continuing Patients on Medications for Opioid Use Disorder—New Challenges for Research and Policy

provide important new evidence on changes in treatment quality across the cascade of care for Medicaid beneficiaries with opioid use disorder (OUD) between 2019 and 2023.Specifically, using Medicaid enrollment and claims records from 47 states and the District of Columbia, they examined changes in the prevalence of OUD diagnoses, medications for OUD (MOUD) treatment, 180-day retention in MOUD treatment, and OUD-related hospitalization or emergency department visits.